Anbio Biotechnology (NNNN) Income Statement (2022 - 2025)
Annual Income Statement report data from Dec 31, 2022 to Dec 31, 2025 for Anbio Biotechnology (NNNN).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
Revenue and COGS | ||||
Total Revenue | 8.65M (+5.62%) | 8.19M (+22.06%) | 6.71M (-71.50%) | 24M |
Cost Of Revenue | 1.10M (-52.17%) | 2.30M (-31.34%) | 3.35M (-69.49%) | 11M |
Costof Goods And Services Sold | 1.10M (-52.17%) | 2.30M (-31.34%) | 3.35M (-69.49%) | 11M |
Gross Profit | 7.54M (+28.01%) | 5.89M (+75.30%) | 3.36M (-73.25%) | 13M |
Operating Expenses | ||||
Research And Development | 200K (-55.56%) | 450K (+246.15%) | 130K (-35.00%) | 200K |
Selling General And Administrative | 1.57M (-54.36%) | 3.44M (+170.87%) | 1.27M (-41.47%) | 2.17M |
Operating Expenses | 1.78M (-54.24%) | 3.89M (+177.86%) | 1.40M (-40.93%) | 2.37M |
Operating Income | ||||
Operating Income | 5.77M (+188.50%) | 2.00M (+2.04%) | 1.96M (-80.78%) | 10M |
Ebit | 5.77M (+188.50%) | 2.00M (+2.04%) | 1.96M (-80.78%) | 10M |
EBITDA | 6.40M (+170.04%) | 2.37M (+5.33%) | 2.25M (-77.54%) | 10M |
Other Income / Expenses | ||||
Interest Income | 140K (-58.82%) | 340K (+100.00%) | 170K (+325.00%) | 40K |
Interest Expense | - | - | - | 10K |
Net Interest Income | 140K (-58.82%) | 340K (+100.00%) | 170K (+325.00%) | 40K |
Other Non Operating Income | 640K (+68.42%) | 380K (+31.03%) | 290K | -180.00K |
Net Income | ||||
Income Before Tax | 6.40M (+170.04%) | 2.37M (+5.33%) | 2.25M (-77.52%) | 10M |
Net Income From Continuing Operations | 6.40M (+170.04%) | 2.37M (+5.33%) | 2.25M (-77.52%) | 10M |
Net Income | 6.40M (+170.04%) | 2.37M (+5.33%) | 2.25M (-77.52%) | 10M |